Reality Check

DAR ES SALAAM (Reuters) - Tanzania has suspended the head of its national health laboratory in charge of testing for the coronavirus and ordered an investigation, a day after President John Magufuli questioned the tests’ accuracy. Magufuli said on Sunday the imported test kits were faulty as they had returned positive results on a goat and a pawpaw — among several non-human samples submitted for testing, with technicians left deliberately unaware of their origins. He did not say where the kits had been imported from or why the authorities had been suspicious of the results. Catherine Sungura, acting head of communications at the ministry of health, said in a statement on Monday the director of the laboratory and its quality assurance manager had been immediately suspended “to pave way for the investigation”. Sungura said a 10-person committee had been formed to investigate the laboratory’s operations, including its process of collecting and testing samples. On Sunday, Magufuli also fired the head of the government Medical Stores Department, which is in charge of distributing medical supplies and equipment to government hospitals, but gave no reason. As of Monday, Tanzania had recorded 480 cases of COVID-19 and 18 deaths, according to a Reuters tally based on government and World Health Organization data. Unlike most other African countries, Tanzania sometimes goes for days without offering updates, with the last bulletin on cases on Wednesday. COVID-19 infections and fatalities reported across Africa have been relatively low compared with the United States, parts of Asia and Europe. But Africa also has extremely low levels of testing, with rates of only around 500 per million people. ADVERTISEMENT

You are oblivious to the point that this GP 120 was inserted into the virus we are dealing with now. Are you familiar with the concept of gain of function? You know what, forget it. I was wrong. Orange man bad, corrupt public officials good. Just do what the government tells you to do, take the shots, as often as possible, and our friend China, who would never collude with imaginary corrupt US officials, will continue to watch our backs while we eat like kings.

When I give my opinion, you dismiss it as an uneducated opinion. When I give information that you can verify on your own, now I am a parrot. You didn't even pick up on the fact that he equated RNA with DNA. How did GP 120, patented by Fauci, making up of12% of the total RNA sequence, get into this new virus? Released from a lab that Fauci does business with in Wuhan. Some people are the definition of the word sheep.

These viruses are RNA only not DNA. Your comparison is ridiculous. Learn the difference between RNA and DNA, then reevaluate your reasoning from scratch. Then we can take this conversation to another level.

Patent number: 9896509 Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV. Type: Grant Filed: August 3, 2016 Date of Patent: February 20, 2018 Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

Over 46,000,000 abortions since 1970. Do they count?

The Mockingbird media is still effective. Not for much longer however...

Dr. Anthony Fauci, whose “expert” advice to President Trump has resulted in the complete shutdown of the greatest economic engine in world history, has known since 2005 that chloroquine is an effective inhibitor of coronaviruses. How did he know this? Because of research done by the National Institutes of Health, of which he is the director. In connection with the SARS outbreak – caused by a coronavirus dubbed SARS- CoV – the NIH researched chloroquine and concluded that it was effective at stopping the SARS coronavirus in its tracks. The COVID-19 bug is likewise a coronavirus, labeled SARS-CoV-2. While not exactly the same virus as SARS-CoV-1, it is genetically related to it, and shares 79% of its genome, as the name SARS-CoV-2 implies. They both use the same host cell receptor, which is what viruses use to gain entry to the cell and infect the victim. The Virology Journal – the official publication of Dr. Fauci’s National Institutes of Health – published what is now a blockbuster article on August 22, 2005, under the heading – get ready for this – “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.” (Emphasis mine throughout.) Write the researchers, “We report…that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage.”

You either didn't read the patents or simply don't understand them.

In 2019, with the backing of NIAID, the National Institutes of Health committed $3.7 million over six years for research that included some gain-of-function work. The program followed another $3.7 million, 5-year project for collecting and studying bat coronaviruses, which ended in 2019, bringing the total to $7.4 million. Many scientists have criticized gain of function research, which involves manipulating viruses in the lab to explore their potential for infecting humans, because it creates a risk of starting a pandemic from accidental release. Ads by scrollerads.com SARS-CoV-2 , the virus now causing a global pandemic, is believed to have originated in bats. U.S. intelligence, after originally asserting that the coronavirus had occurred naturally, conceded last month that the pandemic may have originated in a leak from the Wuhan lab. (At this point most scientists say it's possible—but not likely—that the pandemic virus was engineered or manipulated.) Dr. Fauci did not respond to Newsweek's requests for comment. NIH responded with a statement that said in part: "Most emerging human viruses come from wildlife, and these represent a significant threat to public health and biosecurity in the US and globally, as demonstrated by the SARS epidemic of 2002-03, and the current COVID-19 pandemic.... scientific research indicates that there is no evidence that suggests the virus was created in a laboratory."

Less retirement benefits to pay out.

How did the GP 120 which makes HIV so infectious, patented by Fauci, get into a bat virus? How much money will Fauci and his cronies make on causing and curing a "pandemic"? Do people even care any more?

Publication number: 20030180254 Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. Type: Application Filed: January 23, 2003 Publication date: September 25, 2003 Applicant: The Govt. of the USA as represented by the Secretary of the Dept. of Health & Human Services Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci Patent number: 6548055 Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. Type: Grant Filed: August 9, 2000 Date of Patent: April 15, 2003 Assignee: The United States of America as represented by the Department of Health and Human Services Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci Patent number: 6190656 Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. Type: Grant Filed: September 2, 1997 Date of Patent: February 20, 2001 Assignee: The United States of America as represented by the Department of Health and Human Services Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci Patent number: 6190656 Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. Type: Grant Filed: September 2, 1997 Date of Patent: February 20, 2001 Assignee: The United States of America as represented by the Department of Health and Human Services Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci Patent number: 5696079 Abstract: A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. Type: Grant Filed: May 26, 1995 Date of Patent: December 9, 1997 Assignee: The United States of America as represented by the Department of Health and Human Services Inventors: H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci

Patent number: 9441041 Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV. Type: Grant Filed: September 21, 2015 Date of Patent: September 13, 2016 Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci Publication number: 20160075786 Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV. Type: Application Filed: September 21, 2015 Publication date: March 17, 2016 Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human Serv Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci Publication number: 20090285815 Abstract: Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins. Type: Application Filed: March 21, 2008 Publication date: November 19, 2009 Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci Patent number: 7368114 Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins. Type: Grant Filed: October 24, 2002 Date of Patent: May 6, 2008 Assignee: The United States of America as represented by the Department of Health and Human Services Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci Publication number: 20040265306 Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody or a tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins. Type: Application Filed: July 27, 2004 Publication date: December 30, 2004 Inventors: James Arthos, Claudia Cicala, Anthony S. Fauci

Publication number: 20160333097 Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV. Type: Application Filed: August 3, 2016 Publication date: November 17, 2016 Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

Patent number: 9896509 Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV. Type: Grant Filed: August 3, 2016 Date of Patent: February 20, 2018 Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services Inventors: James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci

The lefties have to win November at all costs, or it will be years before they are relevant again. They are fully aware of this fact.